Final Program - American Society of Gene & Cell Therapy
Final Program - American Society of Gene & Cell Therapy
Final Program - American Society of Gene & Cell Therapy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Wednesday, May 15, 2013<br />
Abstract Directory, Wednesday, May 15, 2013<br />
Oral Abstract Session 131, continued<br />
Cancer Immunotherapy I<br />
3:15 PM - 5:15 PM<br />
Room: Ballroom B<br />
16 5:00 PM<br />
Effective and Safe <strong>Gene</strong>-Modiied T <strong>Cell</strong>s Expressing<br />
High Afinity NYESO-1 Speciic TCR Variants with<br />
Silencing Endogenous TCRs<br />
Sachiko Okamoto, Yasunori Amaishi, Hiroaki Ikeda, Hiroshi Shiku,<br />
Junichi Mineno.<br />
Oral Abstract Session 132<br />
Cancer-Oncolytic Viruses<br />
3:15 PM - 5:15 PM<br />
Room: 150 DEFG<br />
17 3:15 PM<br />
Intraperitoneal (IP) Administration <strong>of</strong> an Oncolytic<br />
Measles Virus (MV) Strain Expressing the Sodium<br />
Iodine Symporter <strong>Gene</strong> in Patients (pts) with Advanced<br />
Ovarian Cancer (OvCa)<br />
Evanthia Galanis, Pamela Atherton, Sean Dowdy, William Cliby,<br />
Paul Haluska, Jr, Harry Long, Ileana Aderca, Keith Knutson,<br />
Matthew Block, Mark Federspiel, Stephen Russell, Kah Whye Peng,<br />
Lynn Hartmann.<br />
18 3:30 PM<br />
In Vivo Expansion <strong>of</strong> a Recipient Population <strong>of</strong> <strong>Cell</strong><br />
Carriers Allows for Highly Effective Systemic Delivery <strong>of</strong><br />
Oncolytic Reovirus Even in the Presence <strong>of</strong> Neutralizing<br />
Antibody<br />
Timothy Kottke, Oliver Donnelly, Elizabeth Ilett, Jill Thompson,<br />
Rosa Diaz, Matt C<strong>of</strong>fey, Peter Selby, Hardev Pandha, Kevin<br />
Harrington, Alan Melcher, Richard Vile.<br />
19 3:45 PM<br />
Baseline Neutralizing Antibody Status Does Not Affect<br />
Intravenous Delivery <strong>of</strong> Oncolytic Vaccinia Pexa-Vec (JX-<br />
594) in Liver Cancer Patients<br />
Caroline J. Breitbach, Jeong Heo, Mong Cho, Anne Moon, Chang<br />
Won Kim, James Burke, Theresa Hickman, Kara Dubois, Yeon<br />
Sook Lee, Manijeh Daneshmand, John C. Bell, Richard Patt, Tae-Ho<br />
Hwang, David H. Kirn.<br />
20 4:00 PM<br />
Induction <strong>of</strong> Antiviral <strong>Gene</strong>s by the Tumor<br />
Microenvironment Confers Resistance to Virotherapy<br />
Yu-Ping Liu, Lukkana Suksanpaisan, Stephen J. Russell, Kah-Whye<br />
Peng.<br />
21 4:15 PM<br />
Superior Antitumoral Activity Induced by a Novel<br />
Oncolytic Adenovirus Armed with an EGFR-Targeted<br />
ImmunoRNase<br />
Ines Fernandez-Ulibarri, Michaela A. E. Arndt, Dominik E. Dorer,<br />
Sarah Engelhardt, Jürgen Krauss, Dirk M. Nettelbeck.<br />
22 4:30 PM<br />
The Oncolytic and Immunotherapeutic Vaccinia<br />
Virus Pexa-Vec (JX-594) Induces Antibody-Mediated<br />
Complement-Dependent Cancer <strong>Cell</strong> Cytolysis<br />
Mi Kyung Kim, Caroline H. Breitbach, Anne Moon, Jeong Heo, Yu<br />
Kyung Lee, Mong Cho, Jun Woo Lee, Seung Geun Kim, Dae Hwang<br />
Kang, Byung Ho Park, John C. Bell, David H. Kirn, Tae-Ho Hwang.<br />
23 4:45 PM<br />
Modulation <strong>of</strong> Innate Immunity with the Anti-CTLA4<br />
Antibody Ipilimumab (Ipi) in Measles Virotherapy for<br />
Glioblastoma<br />
Jayson J. Hardcastle, Hirosha Geekiyanage, Evidio Domingo<br />
Musibay, Cory Allen, Jin Fang, Aaron Johnson, Evanthia Galanis.<br />
24 5:00 PM<br />
Human Bone Marrow-Derived Mesenchymal<br />
Stromal <strong>Cell</strong>s Permit Delivery, and Enhance Eficacy<br />
<strong>of</strong> Systemically Administered Oncolytic Measles<br />
Virotherapy to Disseminated Human Pre-B ALL Murine<br />
Xenograft Models in the Presence <strong>of</strong> Humoral Immunity<br />
Anna Castleton, Aditi Dey, Bella Patel, Brendan Beaton, Anne<br />
Aucher, Daniel Davis, Adele Fielding.<br />
Oral Abstract Session 133<br />
Advancing the Science <strong>of</strong> <strong>Gene</strong> <strong>Therapy</strong> for<br />
Hematologic Diseases<br />
3:15 PM - 5:15 PM<br />
Room: Ballroom C<br />
25 3:15 PM<br />
Improved Chemotherapy Eficacy after MGMT(P140K)<br />
Hematopoietic Stem <strong>Cell</strong> <strong>Gene</strong> <strong>Therapy</strong> in Poor-<br />
Prognosis Glioblastoma by Patient-Speciic<br />
Mathematical Modeling<br />
Jennifer E. Adair, Brian C. Beard, Sandra K. Johnston, Maciej M.<br />
Mrugala, Russell C. Rockne, Kristin R. Swanson, Hans-Peter Kiem.<br />
26 3:30 PM<br />
Therapeutic Levels <strong>of</strong> Anti-Sickling Hemoglobin<br />
Production in Erythroid Progeny <strong>of</strong> Sickle <strong>Cell</strong> Disease<br />
CD34+ <strong>Cell</strong>s Following Lentivirus Vector-Mediated <strong>Gene</strong><br />
Delivery<br />
Fabrizia Urbinati, Phillip W. Hargrove, Sabine Geiger, Zulema<br />
Romero, Jennifer Wherley, Michael L. Kaufman, Roger P. Hollis,<br />
Christopher B. Chambers, Derek A. Persons, Donald B. Kohn,<br />
Andrew Wilber.<br />
27 3:45 PM<br />
Superior Stem <strong>Cell</strong> Mobilization by a Combination <strong>of</strong><br />
Plerixafor+G-CSF in Patients with Thalassemia<br />
Evangelia Yannaki, Achilles Anagnostopoulos, Garyfalia<br />
Karponi, Fani Zervou, Varnavas Constantinou, Nikoleta Psatha,<br />
Asimina Bouinta, Erica Jonlin, Thalia Papayannopoulou, George<br />
Stamatoyannopoulos.<br />
88<br />
<strong>Final</strong> <strong>Program</strong> SALT LAKE CITY, UTAH May 15–18, 2013
Change language